Alembic Pharma gets USFDA nod for generic drug to treat breast cancer

The approval granted by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA), Fulvestrant injection of strength 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, the company said in a statement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LTCn475
via IFTTT